GlaxoSmithKline increases share in Theravance

Drugs giant GlaxoSmithKline has agreed to up its stake in US biotech firm Theravance, its partner in lung medicine Relovair.

It is to pay $212.9m (€159.5m) to increase its holding from 18.3% to 26.8%.